Avalo Therapeutics Stock Investor Sentiment

AVTX Stock  USD 9.55  0.44  4.40%   
Slightly above 61% of Avalo Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Avalo Therapeutics suggests that many traders are alarmed. Avalo Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Avalo Therapeutics' earnings reports, geopolitical events, and overall market trends.
  

Avalo Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Avalo Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a week ago at news.google.com         
Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Neil Garry Arthur of 4000 shares of Avalo Therapeutics at 3.42 subject to Rule 16b-3
Macroaxis News
over a week ago at gurufocus.com         
Orbimed Advisors LLC Acquires New Stake in Avalo Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at investing.com         
Avalo Therapeutics director June Almenoff acquires 12,749 in stock
Investing News at Macroaxis
over two weeks ago at www.macroaxis.com         
Acquisition by Almenoff June Sherie of 500 shares of Avalo Therapeutics at 13.0 subject to Rule 16b-...
Macroaxis News
over two weeks ago at finance.yahoo.com         
Avalo Therapeutics Receives 69.4 Million in Proceeds from the Full Exercise of Private Placement War...
Yahoo News
over two weeks ago at finance.yahoo.com         
Acquisition by Almenoff June Sherie of 500 shares of Avalo Therapeutics at 12.499 subject to Rule 16...
Yahoo News
over two weeks ago at globenewswire.com         
Avalo Therapeutics to Present at Upcoming Investor Conferences
Macroaxis News: globenewswire.com
over two weeks ago at seekingalpha.com         
Avalo Therapeutics GAAP EPS of -2.83, revenue of 0.25M
seekingalpha News
over two weeks ago at finance.yahoo.com         
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
Yahoo News
over three weeks ago at www.macroaxis.com         
Acquisition by Truex Samantha of 24600 shares of Avalo Therapeutics at 9.88 subject to Rule 16b-3
Macroaxis News
over a month ago at globenewswire.com         
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidraden...
Macroaxis News: globenewswire.com
over two months ago at news.google.com         
Where are the Opportunities in - Stock Traders Daily
Google News at Macroaxis
over two months ago at thelincolnianonline.com         
Avalo Therapeutics, Inc. Short Interest Update
news
over two months ago at finance.yahoo.com         
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Yahoo News
Far too much social signal, news, headlines, and media speculation about Avalo Therapeutics that are available to investors today. That information is available publicly through Avalo media outlets and privately through word of mouth or via Avalo internal channels. However, regardless of the origin, that massive amount of Avalo data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Avalo Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Avalo Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Avalo Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Avalo Therapeutics alpha.

Avalo Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Avalo Announces Participation in September Investor Conferences
09/04/2024
2
Where are the Opportunities in - Stock Traders Daily
09/24/2024
3
Acquisition by Truex Samantha of 24600 shares of Avalo Therapeutics at 9.88 subject to Rule 16b-3
11/01/2024
4
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
11/07/2024
5
Avalo Therapeutics Receives 69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
11/12/2024
6
Acquisition by Almenoff June Sherie of 500 shares of Avalo Therapeutics at 13.0 subject to Rule 16b-3
11/13/2024
7
Avalo Therapeutics director June Almenoff acquires 12,749 in stock
11/14/2024
8
Acquisition by Neil Garry Arthur of 4000 shares of Avalo Therapeutics at 3.42 subject to Rule 16b-3
11/18/2024
9
Avalo Therapeutics receives 69.4M in proceeds from full exercise of private placement warrants - MSN
11/20/2024

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.